Inclusion Criteria:

          -  Histologically confirmed solid tumors that have progressed on or intolerant to
             standard therapy or whom no standard therapy exists

          -  ECOG (electrocorticogram) performance status 0~1

          -  Life expectancy ≥ 3 months

          -  Adequate organ function and bone marrow function

        Exclusion Criteria:

          -  Known allergy or hypersensitivity to any component of the investigational drug product
             Previous treatment with CSF-1(colony stimulating factor 1)/CSF-1R (colony stimulating
             factor 1 receptor) pathway inhibitors

          -  Known additional malignancy that is progressing or required active treatment within 3
             years of the first dose of study treatment

          -  Inability to take oral medication or significant nausea and vomiting, malabsorption,
             external biliary shunt, or significant bowel resection that would preclude adequate
             absorption of oral medication

          -  Previous anti-cancer therapy, including chemotherapy, radiotherapy, endocrine therapy
             or molecular targeted therapy within ≤ 5-halflife or ≤ 4 weeks (whichever is shorter)
             prior to initiation of study treatment (chemotherapy with nitrosourea or mitomycin
             should be 6 weeks prior to initiation of study treatment)

          -  Major surgery within 4 weeks of the first dose of study drug and all surgical wounds
             must be healed and free of infection or dehiscence

          -  Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies,
             including immunotherapy that have not regressed to Grade ≤2 severity (CTCAE v5.0) with
             the exception of alopecia and vitiligo

          -  Prior corticosteroids as anti-cancer therapy within a minimum of 2 weeks of the first
             dose of study drug

          -  Concomitant use of strong inhibitors or inducers of CYP3A4

          -  Active central nervous system (CNS) metastases

          -  Impaired cardiac function or clinically significant cardiac disease

          -  Patients with Gilbert's Syndrome or other underlying conditions that may lead to a
             greater likelihood of developing LFT(liver function test) abnormalities during the
             study

          -  Known human immunodeficiency virus or active hepatitis B, or active hepatitis C
             infection

          -  Refractory/uncontrolled ascites or pleural effusion

          -  Pregnant or nursing